The purpose of this study is to evaluate the tolerability and efficacy of surufatinib in Japanese patients.~The study will be conducted in 2 parts:~Part 1 - evaluation of tolerability and safety of surufatinib and confirmation of the recommended clinical dose in Japanese patients with nonhematologic malignancies~Part 2 - evaluation of antitumor activity and confirmation of tolerability of surufatinib in Japanese patients with NETs~All patients will be treated with oral surufatinib 300 mg QD in treatment cycles of 28 days starting on Cycle 1 Day 1.
This is a phase 1/2, open-label, multi-centre study of surufatinib in patients with unresectable, locally advanced, or recurrent nonhematologic malignancies who do not respond or are intolerant to standard of care.